JAGSNPHARM

Jagsonpal Pharmaceuticals Share Price

 

 

Invest in Jagsonpal Pharmaceuticals with 2.21X leverage

Invest with MTF

Performance

  • Low
  • ₹166
  • High
  • ₹172
  • 52 Week Low
  • ₹155
  • 52 Week High
  • ₹302
  • Open Price₹170
  • Previous Close₹170
  • Volume50,826
  • 50 DMA₹185.70
  • 100 DMA₹199.58
  • 200 DMA₹209.60

Investment Returns

  • Over 1 Month -12.21%
  • Over 3 Month -22.16%
  • Over 6 Month -37.28%
  • Over 1 Year -36.94%

Smart Investing Starts Here Start SIP with Jagsonpal Pharmaceuticals for Steady Growth!

Invest Now

Jagsonpal Pharmaceuticals Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 27.5
  • PEG Ratio
  • -1.3
  • Market Cap Cr
  • 1,125
  • P/B Ratio
  • 4.4
  • Average True Range
  • 7.22
  • EPS
  • 6.37
  • Dividend Yield
  • 1.5
  • MACD Signal
  • -6.86
  • RSI
  • 39.32
  • MFI
  • 33.75

Jagsonpal Pharmaceuticals Financials

Jagsonpal Pharmaceuticals Technicals

EMA & SMA

Current Price
₹168.16
-1.91 (-1.12%)
pointer
  • Bearish Moving Average 16
  • Bullish Moving Average 0
  • 20 Day
  • ₹173.42
  • 50 Day
  • ₹185.70
  • 100 Day
  • ₹199.58
  • 200 Day
  • ₹209.60

Resistance and Support

168.48 Pivot Speed
  • R3 177.71
  • R2 174.74
  • R1 171.45
  • S1 165.19
  • S2 162.22
  • S3 158.93

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Jagsonpal Pharmaceuticals manufactures and markets pharmaceutical formulations, focusing on therapeutic areas like gynecology, orthopedics, and cardiovascular health. It serves both domestic and international markets, providing high-quality medicines to improve healthcare outcomes.

Jagsonpal Pharmaceuticals has an operating revenue of Rs. 281.58 Cr. on a trailing 12-month basis. An annual revenue growth of 27% is outstanding, Pre-tax margin of 26% is great, ROE of 23% is exceptional. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 50 which is a POOR score indicating inconsistency in earnings, a RS Rating of 17 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at C- which is evident from recent supply seen, Group Rank of 79 indicates it belongs to a poor industry group of Medical-Diversified and a Master Score of D is close to being the worst. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Jagsonpal Pharmaceuticals Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-01-21 Quarterly Results
2025-11-03 Quarterly Results
2025-07-26 Quarterly Results
2025-05-06 Audited Results & Final Dividend
2025-01-22 Quarterly Results
Date Purpose Remarks
2025-09-12 FINAL Rs.2.50 per share(125%)Final Dividend
2024-09-06 FINAL Rs.5.00 per share(100%)Final Dividend
2023-08-21 FINAL Rs.5.00 per share(100%)Dividend
2021-11-01 INTERIM Rs.4.00 per share(80%)Interim Dividend
View Jagsonpal Pharmaceuticals Dividend History Arrow
Date Purpose Remarks
2025-01-08 Split Rs.0.00 split from Rs. 5/- to Rs. 2/-.

Jagsonpal Pharmaceuticals F&O

Jagsonpal Pharmaceuticals Shareholding Pattern

67.39%
0%
2.12%
0%
21.2%
9.29%

About Jagsonpal Pharmaceuticals

  • NSE Symbol
  • JAGSNPHARM
  • BSE Symbol
  • 507789
  • Managing Director
  • Mr. Manish Gupta
  • ISIN
  • INE048B01035

Similar Stocks to Jagsonpal Pharmaceuticals

Jagsonpal Pharmaceuticals FAQs

Jagsonpal Pharmaceuticals share price is ₹168 As on 08 February, 2026 | 08:26

The Market Cap of Jagsonpal Pharmaceuticals is ₹1124.8 Cr As on 08 February, 2026 | 08:26

The P/E ratio of Jagsonpal Pharmaceuticals is 27.5 As on 08 February, 2026 | 08:26

The PB ratio of Jagsonpal Pharmaceuticals is 4.4 As on 08 February, 2026 | 08:26

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23